Nutritional Growth Solutions Ltd (ngs) Logo

Nutritional Growth Solutions Ltd (NGS)

___:___ · Consumer Defensive

NGS Chart


NGS's Principal Activity is the direct sale of products to end customers.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -60.20%
vs ASX 200 (1yr) -49.99%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 2,088 of 2,427
Sector Rank 84 of 96

Key Fundamentals

Shares Issued
Sector Consumer Defensive
Similar Companies FFF / FRM / LV1
EPS -$0.047
DPS $0.00
Book Value Per Share $0.05

Broker Consensus

NGS is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Nutritional Growth Solutions Ltd (NGS) is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into paediatric nutrition at Schneider Children's Medical Centre, Israel's paediatric hospital.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Tel Aviv Israel 6971068
Registry Automic Group
Auditor BDO Ziv Haft
Date Listed 30 Oct 2020

Upcoming Calendar (Forecasted)

Date Event
18/08/2022 Report (Interim)
24/02/2023 Report (Prelim)
30/03/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr David (Dave) Fenlon Non-Executive Chairman,Non-Executive Director Feb 2022

Mr David (Dave) Fenlon

Non-Executive Chairman,Non-Executive Director

Mr Fenlon has over 30 years' experience in retail and consumer goods across Europe, Australasia and North America. Until very recently he was the Managing Director & CEO of leading beauty and wellness business BWX Limited (ASX: BWX) and was previously Managing Director - Australia & NZ for Blackmores Limited (ASX: BKL). In addition, Mr Fenlon is currently a Non-executive Director of Quest for Life Foundation, an Australian not-for-profit organisation dedicated to supporting people through personal traumas.

Ms Lisa Wynne Company Secretary Dec 2020
Ms Liron Fendell Chief Executive Officer,Managing Director Oct 2020

Ms Liron Fendell

Chief Executive Officer,Managing Director

Ms Fendell has experience in nutrition, emerging technology and global child health. Ms Fendell was previously a corporate lawyer in one of Tel Aviv's law firms, representing bio tech start-ups as well as pharmaceutical companies, and gaining experience in structuring, negotiating and executing business transactions. Since 2012, Ms Fendell has served as a board member of CPC - Children Playing Chess, a non-profit organization. Struggling with her own children's nutrition and growth, Ms Fendell joined the Company on its creation in 2014 to work with the founding doctors at Schneider in order to convert the clinical knowledge and data into tangible products and commercial business.

Dr Kinneret Livnat Savitzky Non-Executive Director Oct 2020

Dr Kinneret Livnat Savitzky

Non-Executive Director

Dr Livnat Savitzky has experience in the life sciences industry, including drug discovery and development, corporate partnering and capital raising. Dr Livnat Savitzky currently serves as the CEO and a board member of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners. Johnson & Johnson Innovation and Takeda Ventures Inc. (the venture group of Takeda Pharmaceutical Company). Dr Livnat Savitzky also serves on the boards of several biotechnology or healthcare companies. From 2010 to 2016. Dr Livnat Savitzky served as the CEO of NASDAQ-listed BioLineRx Ltd. Prior to being appointed CEO of BioLineRx. she held various research and development management positions at BioLineRx and Compugen. She is also member of Risk Committee of the Company.

Dr Anton Uvarov Non-Executive Director Oct 2020

Dr Anton Uvarov

Non-Executive Director

Dr Uvarov has experience as an advisor to the healthcare industry with a focus on the biotechnology sector both in Australia and internationally, and has been involved in funding numerous biotechnology and pharmaceutical companies. He is a former equities research analyst with Citigroup, US. Dr Uvarov is a founding director of Actinogen Medical (ASX:ACW), a clinical stage biotechnology company and is an Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), a biotechnology company developing new treatments for neurodegenerative diseases. Dr Uvarov is a former Director of Elsight Limited (ASX:ELS) and Parazero Limited (ASX:PRZ). He is also member of Risk Committee of the Company.

Mr Amir Zaidman Non-Executive Director Oct 2020

Mr Amir Zaidman

Non-Executive Director

Mr Zaidman has more than 20 years of experience in business development and venture capital investments. Since 2014, Mr Zaidman has served as the vice president of business development of "The Kitchen Hub" - the first FoodTech focused seed investor and technology incubator in Israel. In this capacity he provides business development and marketing support to portfolio companies and is also in charge of The Kitchen Hub's new investments, and has led the investment process in 18 portfolio companies to date. Mr Zaidman serves on the board of directors of numerous private FoodTech companies. Mr Zaidman is a executive in the FoodTech community in Israel. He created and manages the Israel FoodTech Innovation Linkedln group as well as the Israel's FoodTech Community MeetUp group. He is also Chair of Risk Committee of the Company.

Professor Raanan Shamir Chief Medical Officer,Executive Director Jan 2014

Professor Raanan Shamir

Chief Medical Officer,Executive Director

Prof Shamir is Chairman of the Institute of Gastroenterology, Nutrition and Liver Diseases at Schneider. In the early 90s, he was a fellow at the Division of Pediatric Gastroenterology and Nutrition at The Children's Hospital of Philadelphia. Prof Shamir has published approximately 400 original papers, reviews and comments, book chapters and guidelines. His current research areas include paediatric nutrition, nutrition and growth, celiac disease, inflammatory bowel disease and childhood hyperlipidemia. Prof Shamir is a co-founder of the Company.

Director Transactions

NGS directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
19/11/21 Brian Leedman Issued 58,140 $0.185 $10,755 Placement
19/11/21 Brian Leedman Issued 232,558 $0.215 $49,999 Placement
19/11/21 Brian Leedman Transfer 1,500,000 $0.185 $277,500 Off-market transfer
19/11/21 Brian Leedman Transfer 1,500,000 $0.185 $277,500 Off-market transfer
19/11/21 Anton Uvarov Issued 50,000 $0.185 $9,250 Placement
19/11/21 Anton Uvarov Issued 200,000 $0.215 $43,000 Placement

Director Interests

The current holdings of NGS directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
David (Dave) Fenlon 28/02/2022 0 N/A N/A N/A
Anton Uvarov 19/11/2021 N/A 1,889,290 50,000 N/A
Amir Zaidman 28/10/2020 0 N/A N/A N/A
Kinneret Livnat Savitzky 28/10/2020 0 N/A N/A N/A
Liron Fendell 28/10/2020 N/A N/A 4,314,286 N/A
Raanan Shamir 05/01/2014 4,465,470 N/A 1,114,286 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Mar 16, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Mor Research Applications Ltd 12,604,790 10.68%
Ms Hadassa Bymel 8,098,652 6.86%
Prof Phillip Moshe 5,028,720 4.26%
Prof Raanan Shamir 4,465,470 3.78%
Prof Lazar Liora 3,151,184 2.67%
Dr Michal Gavan 3,151,184 2.67%
Moshe Cohen 3,107,143 2.63%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,975,389 2.52%
Netwealth Investments Limited <Super Services A/C> 2,610,162 2.21%
Mr Marx Lin 2,300,000 1.95%
Netwealth Investments Limited <Wrap Services A/C> 1,920,579 1.63%
Ms Yulia Uvarova <Techinvest Nominees A/C> 1,889,290 1.60%
Blackchess Investment Pty Ltd 1,700,000 1.44%
Mr Narinder Singh Sudagar Singh <Sidhu A/C> 1,657,429 1.40%
BNP Paribas Noms Pty Ltd <Drp> 1,643,171 1.39%
Impact Equities Pty Ltd 1,626,000 1.38%
Arq Capital Pty Ltd <Nitsche Family A/C> 1,571,571 1.33%
Citicorp Nominees Pty Limited 1,562,534 1.32%
Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> 1,500,001 1.27%
Mr Brian Leedman & Mrs Natasha Leedman 1,440,000 1.22%
Gcn Investments Pty Ltd <Seveen Superfund A/C> 1,100,000 0.93%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 17 159 90 400 163 829

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Hadassa Bymel Pharmacy & Nature Ltd 16/03/2022 8,098,652 6.86
Mor Research Applications Ltd 16/03/2022 12,604,790 10.68

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.24 30 June
NGS Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.